By Jennifer C. King, PhD, Director of Science & Research at Lung Cancer Alliance Research on the treatment of lung cancer has been moving quickly and 2017 was no different. Precision medicine was a key theme this year - [...]
LCAM 2017 This November was the most impactful Lung Cancer Awareness Month (LCAM) to date! With your efforts, time and ongoing support we were able to reach more people, raise more awareness and ignite more change than ever before. [...]
Jennifer C. King, PhD, Director of Science & Research at Lung Cancer Alliance, sits down with Research!America to discuss the impact research has had on the lung cancer community and what's to come down the line. Read on! [...]
Monday, November 6, 2017 – Today, Lung Cancer Alliance (LCA) joins the Memorial Sloan Kettering Cancer Center (MSK) and the NYU School of Medicine (NYU) to announce the launch of the Cessation And Screening To Save Lives (CASTL) Initiative. [...]
Today, the Food and Drug Administration (FDA) approved the first combination of chemotherapy and immunotherapy for patients with lung cancer. Patients with metastatic, nonsquamous, non-small cell lung cancer can now take Keytruda (pembrolizumab) immunotherapy along with chemotherapy (pemetrexed and [...]